Skip to main content

Table 2 Comparison of biomarkers according to survival status

From: Autotaxin levels in serum and bronchoalveolar lavage fluid are associated with inflammatory and fibrotic biomarkers and the clinical outcome in patients with acute respiratory distress syndrome

Biomarkers BALF Serum
ARDS survivors
(n = 31)
ARDS non-survivors
(n = 21)
ARDS survivors
(n = 31)
ARDS non-survivors
(n = 21)
ATX (ng/mL) 3.19 ± 4.43 3.04 ± 3.46 35.09 ± 13.89 44.79 ± 13.38*
IL-6 (ng/mL) 0.39 ± 0.56 0.61 ± 0.63 0.89 ± 3.83 0.97 ± 2.01
IL-8 (ng/mL) 3136.77 ± 1915.69 4618.65 ± 2776.99* 258.76 ± 735.09 314.47 ± 478.16
TNF-α (pg/mL) 13.27 (8.00-51.13) 35.56 (9.47-192.87) 12.04 (8.20-23.99) 14.72 (6.17-37.86)
MMP-7 (ng/mL) 34.03 ± 28.85 46.30 ± 43.18 4.81 (2.75-7.76) 8.02 (4.43-16.73) *
Fibronectin (ug/mL) 1.12 ± 1.74 1.12 ± 1.65 72.26 ± 111.07 78.21 ± 98.01
OSM (ng/mL) 0.93 ± 0.66 1.22 ± 0.76 3.65 ± 3.81 3.83 ± 5.25
SPARC (ng/mL) 19.50 ± 56.28 15.84 ± 37.57 1.33 ± 0.92 1.03 ± 0.12
  1. Data are presented as the mean ± standard deviation or median (interquartile range). Statistical significance was set at P<0.05. ARDS, acute respiratory distress syndrome; ATX, autotaxin; BALF, bronchoalveolar lavage fluid; IL-6, interleukin-6; IL-8, interleukin-8; MMP-7, matrix metalloproteinase-7; OSM, oncostatin M; SPARC, secreted protein acidic and rich in cysteine; TNF-α, tumor necrosis factor-α *P<0.05 vs survivors